Dermira, Inc.: Series A $42M

Posted in I - Series A, Q - 4Q11, R - WEST, X - Dermatology, X - Inflammation, XX - CA

Dermira (Redwood City, CA) a clinical-stage pharmaceutical company focused on topical treatments and light therapy for acne and inflammatory skin disease, closed a $42M Series A financing. Participants include Bay City Capital, New Enterprise Associates and Canaan Partners.

Jan

2012

Aviir, Inc.: Series E $10M

Posted in I - Series E, Q - 4Q11, R - WEST, X - Cardiology, X - Device (Diagnostic), X - Metabolism, XX - CA

Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Oct

2011

Nevro Corp.: Series B $58M

Posted in I - Series B, Q - 3Q11, R - WEST, X - Device (Neuromodulation), XX - CA

Nevro (Menlo Park, CA) a clinical-stage medical device company focused on neuromodulation for the relief of chronic pain, closed a $58M Series B financing. Participants include Johnson & Johnson Development Corp, Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, MPM Capital and Three Arch Partners.

May

2011

Conatus Pharmaceuticals, Inc.: Series B $20M

Posted in I - Series B, Q - 1Q11, R - WEST, X - Hepatitis C, X - Oncology, XX - CA

Conatus Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on hepatic disease and oncology, closed a $20M Series B financing. Participants include AgeChem Venture Fund, Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners and Roche Venture Fund.

Apr

2011

NextWave Pharmaceuticals, Inc.: Series C $45M

Posted in I - Series C, Q - 1Q11, R - WEST, X - Cardiology, X - CNS, XX - CA

NextWave Pharmaceuticals (Cupertino, CA) a clinical-stage specialty pharmaceutical focused on cardiovascular and CNS diseases, closed a $45M Series C financing. Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.

Jan

2011

IDEV Technologies, Inc.: Series D $46M

Posted in I - Series D, Q - 4Q10, R - SOUTH WEST, X - Device (Stent), XX - TX

IDEV Technologies (Webster, TX) a clinical-stage medical device company focused on endovascular and interventional stents, closed a $46M Series D financing. Participants include Piper Jaffray, PTV Sciences, Bay City Capital, RiverVest Venture Partners and Heron Capital.

Mar

2010

Merus, B.V.: Series B $30.7M

Posted in I - Series B, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology

Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

Feb

2010

Epizyme, Inc.: Series B $8M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Jan

2010

Epizyme, Inc.: Series B $32M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...